Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose 5% provides caloric support and may help prevent ketosis. Sodium chloride 0.33% provides sodium and chloride ions to maintain electrolyte balance and osmotic pressure.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion at a rate determined by serum potassium levels; typical maintenance: 10-20 mEq potassium per hour, not to exceed 40 mEq/hour; maximum daily dose: 200 mEq. Adjust based on patient's electrolyte status and renal function.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal half-life is approximately 2-4 hours in patients with normal renal function. Clinical context: half-life extends significantly in renal impairment (e.g., up to 24-48 hours in oliguric patients) and is dependent on total body potassium stores and redistribution kinetics.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (90%) with minor fecal (10%) losses. Renal elimination involves glomerular filtration and distal tubular secretion; 80-90% is reabsorbed, with excretion adjusted by aldosterone. In dextrose/saline, potassium excretion parallels sodium and water handling.
Category C
Category A/B
Electrolyte
Electrolyte